Skip to main content
. Author manuscript; available in PMC: 2016 Oct 22.
Published in final edited form as: Brain Res. 2015 Aug 10;1624:359–369. doi: 10.1016/j.brainres.2015.07.057

Fig. 3. Effect of GSNO treatment on GSK-3β activation under chronic cerebral hypoperfusion.

Fig. 3

A. GSK-3β activities were analyzed in sham, pBCCAO rats, and pBCCAO rats treated with GSNO by in vitro kinase assay as described under experimental procedure. B. In addition, the effect of GSNO treatment on the phosphorylation status of Tyr279 (GSK3α)/Tyr216 (GSK-3β) or Ser9 of GSK-3β was analyzed by Western blot using specific antibody. The vertical columns are the means of individual data and T-bars are the standard error mean. ***p<0.0001; and as compared to sham group. ++p<0.005 as compared to untreated pBCCAO group.